"Increasingly, big pharma has been looking to biotech's preclinical and early-stage candidates to infuse their own pipelines with more innovation, and the up-front and milestone payments and favorable deal terms of these licensing collaborations reflect the value that many large pharma companies place on promising early candidates. Early-stage deal-makers from both big pharma and biotech will discuss how companies should evaluate their portfolio to determine what candidates should be selected for licensing and why. Panelists will also cover the types of deals to look for, innovative deal structures and the increasing value expectations attached to earlier-stage deals."

Objective1:Educate earlier-stage candidates on what big pharma is looking for and how to strategically choose which candidates to license out.

Objective2:"Provide information on how these license and collaboration agreements should be approached, negotiated and structured."

Objective3:Give an experiential view, via case studies, of companies that have done these deals or are working toward securing them.